Back to Home

Provider Network Models

Expert articles and analysis related to provider network models.

199 articles•Last 7 Days

AI Summary — Last 7 Days

CMS is moving on two network-relevant VBC fronts: the ACCESS chronic care model is adding concrete OAP billing rules and 2026–2027 payment/performance targets, signaling tighter operational expectations for scalable chronic-care networks, while the GENEROUS Medicaid drug pricing model now has all states participating, creating a national Medicaid cost-containment framework that could reshape pharmacy strategy inside risk-bearing provider and payer networks. For ACOs, MA plans, and Medicaid managed care organizations, the week’s throughline is that CMS is pairing broader mandatory or near-universal participation with more data- and outcome-linked payment mechanics—raising stakes around attribution, documentation, pharmacy integration, and performance measurement, especially as Medicare quality bonuses face repricing based on data infrastructure rather than care changes (ACCESS payment targets, [

Related Articles

95ALN

How TrumpRx Brand-Name Drug Prices Compare to Other Countries

TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without...

KFFSep 24, 2026
95ALN

Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive

Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those...

KFFSep 24, 2026
95ALN

Florida AG sues PBMs, pharmas over rise in insulin prices

Florida AG sues PBMs, pharmas over rise in insulin prices  Fierce Healthcare

Fierce HealthcareSep 23, 2026
95ALN

The Role of Comparator Selection in Ex-US HTA and International Drug Pricing

AvalereSep 21, 2026
95ALN

Pfizer, Lilly 'most favored nation' deals to give US share of raised foreign prices

The "most favored nation" drug pricing deals that Pfizer and Eli Lilly signed with the Trump administration suggest the companies will give the government a share of increased revenue they generate fr...

Endpoints NewsSep 21, 2026
92ALN

Hospitals are scrambling to keep 340B discounts. Here’s what to know

Hospitals are scrambling to keep 340B discounts. Here’s what to know  Modern Healthcare News

Modern HealthcareSep 25, 2026
92ALN

FAQ: How the GENEROUS Model Applies MFN Pricing to Medicaid

Pharmaceutical CommerceSep 21, 2026
90ALN

Report: High Drug Costs Are Creating Hidden Burden for Physicians

Report: High Drug Costs Are Creating Hidden Burden for Physicians  MedCity News

MedCity NewsSep 25, 2026
90ALN

Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes

Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes  Becker's Hospital Review

Becker's Hospital ReviewSep 25, 2026
90ALN

Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes

Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes  Becker's Hospital Review

Becker's Hospital ReviewSep 25, 2026